SCHEMBL6822330

SCHEMBL6822330

CCC(OC)n1nc(-c2c(-c3ccccc3)nn3ccc(OC)cc23)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.41
TP53 P04637 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
IGF1R P08069 1/20 0.35
POLB P06746 2/20 0.35
FGFR1 P11362 2/20 0.35
FGFR2 P21802 2/20 0.35
FGFR3 P22607 2/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
TSHR P16473 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CASR P41180 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
MAPK1 P28482 1/20 0.33
PTGER1 P34995 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6821959 0.87 ADORA1 (0.42) ADORA1IGF1RFGFR1FGFR2FGFR3
SCHEMBL6822329 0.85 ADORA1 (0.41) ADORA1TP53MAPTSMN1; SMN2IGF1R
SCHEMBL6821431 0.83 ADORA1 (0.51) ADORA1IGF1RKDM4EHSD17B10PTGDR2
SCHEMBL6822006 0.82 ADORA1 (0.46) ADORA1TP53IGF1RLMNACASR
SCHEMBL6822151 0.82 ADORA1 (0.54) ADORA1IGF1RHSD17B10PTGDR2
SCHEMBL6822058 0.81 ADORA1 (0.42) ADORA1TP53IGF1RPOLBLMNA
SCHEMBL6822483 0.79 CMKLR1 (0.42) ADORA1SMN1; SMN2KDM4ECASR
SCHEMBL6822546 0.79 ADORA1 (0.41) ADORA1MAPTIGF1RCASR
SCHEMBL6821470 0.79 ADORA1 (0.36) ADORA1MAPTIGF1RFGFR1FGFR2
SCHEMBL6822257 0.79 ADORA1 (0.43) ADORA1TP53SMN1; SMN2IGF1RPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885TP53 4085/4885MAPT 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.